Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement
Bayer Schering Pharma AG, Germany, has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics, Inc. for the development and commercialization of Vaginorm, an intra-vaginal application of dehydroepiandrosterone (DHEA).
Original Source of Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement
